Shoreline Biosciences and BeiGene Announce Global Strategic Collaboration to Develop and Commercialize Genetically Engineered Natural Killer (NK) Cell Therapies

SAN DIEGO & CAMBRIDGE, Massachusetts & BEIJING – (COMMERCIAL THREAD) – Shoreline Biosciences, Inc., a biotechnology company developing ready-to-use, standardized and targeted allogeneic cellular immunotherapies and cellular macrophages derived from induced pluripotent stem cells (iPSCs) for cancer and other serious diseases, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a global biotechnology company, today announced an exclusive global strategic collaboration to develop and commercialize a portfolio of NK-based cell therapies with Shoreline’s iPSC NK cell technology and research and developmental capacities for different malignancies.

“BeiGene is a globally recognized biotechnology leader and we are delighted to announce our collaboration today,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Chairman & CEO. “We look forward to combining our iPSC NK cells with BeiGene’s discovery and clinical development expertise as the parties strive to accelerate the development of the next generation of cell therapies for patients around the world. ”

Under the terms of the agreement, Shoreline will receive an initial cash payment of $ 45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based on the achievement of certain milestones of the agreement. development, regulatory and commercial. As part of the multi-target collaboration, the companies have agreed to work jointly to develop cell therapies for four designated therapeutic targets, with the possibility of expanding the collaboration at a later date. Clinical development will be led by BeiGene globally, with Shoreline responsible for clinical manufacturing. BeiGene will hold the commercial rights globally, with Shoreline having the option of retaining the commercial rights in the United States and Canada for two targets. As part of the deal, BeiGene has an option to acquire a stake in Shoreline in its next round of equity financing, subject to specified conditions.

“We are delighted to collaborate with Shoreline as BeiGene seeks to expand our portfolio of transformative drugs, from small molecule and antibody therapies to standard cell therapies, a fascinating area of ​​research that has been primarily beyond the reach of many patients,” said John V. Oyler, co-founder, president and CEO of BeiGene. “We look forward to collaborating with Shoreline, a leading company in the development of allogeneic cell therapies derived from iPSC, as we combine our protein engineering technologies with Shoreline’s standardized NK cell therapy technology. We hope that this combination, along with our expertise in clinical development for solid tumors and hematologic malignancies, will bring cell therapies to more patients who need them. ”

About Shoreline iPSC NK Cellular Technology

Shoreline has developed a proprietary platform focused on iPSC-derived natural killer (NK) cells and macrophages that are optimized with precise and rational genetic reprogramming. Cellular therapies based on NK cells and Shoreline macrophages are designed to provide an effective and efficient means of targeting and killing tumors as well as repairing tissue homeostasis. Shoreline’s approach, based on the advantage of its cellular engineering and iPSC expansion, is used to create a streamlined, affordable and scalable manufacturing process that can deliver cell therapy treatments to patients in a more cost-effective and efficient manner. fast. Shoreline’s technology is at the forefront of regenerative medicine and is used to develop potential therapies to treat a wide range of diseases, including cancer, inflammatory and genetic diseases.

About Shoreline Biosciences

Shoreline is a biotechnology company dedicated to advancing the development of ready-to-use, targeted and standardized allogeneic cellular immunotherapies intelligently designed for cancer and other serious diseases. Shoreline is building a pipeline of natural killer cell (NK) and macrophage cell therapy candidates derived from its deep expertise in iPSC differentiation methods and genetic reprogramming of disease-relevant pathways. Shoreline has a strategic manufacturing relationship with the Advanced Cell Therapy Lab and is backed by high quality institutional investors including Boxer Capital, BVF, Commodore, Cormorant, Janus Henderson Investors, Logos, Kite, A Gilead Company, Wedbush Healthcare Partners , Stork Capital, and others. Shoreline Biosciences is headquartered in San Diego, California.

For more information, please visit https://shorelinebio.com/ and contact us on LinkedIn.

About BeiGene

BeiGene is a science-driven global biotechnology company focused on the development of innovative and affordable medicines to improve treatment outcomes and access for patients around the world. With a large portfolio of more than 40 clinical candidates, we are committed to accelerating the development of our diverse portfolio of new therapies through collaborations or our own internal capacities, with the ambitious goal of radically improving access to medicines for two billion more people by 2030. BeiGene is by design a company without a head office, with a growing global team of around 6,000 colleagues on five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

BeiGene forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the future development and potential commercialization of therapeutic candidates using licensed technology. ; potential payments to Shoreline Biosciences; the potential of the licensed technology; and the parties’ commitments and the potential benefits of collaboration. Actual results may differ materially from those shown in forward-looking statements due to various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results of its drug candidates, which may not support further development or marketing authorization; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene’s ability to obtain and maintain intellectual property protection for its technology and drugs; BeiGene’s dependence on third parties for drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene’s ability to secure additional funding for its operations and complete the development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on the Company’s clinical development, business and other operations, as well as the risks discussed in more detail in the section titled “Risk Factors” of BeiGene’s latest quarterly report on the form 10-Q, as well as discussions of potential risks, uncertainties and other important factors in BeiGene’s subsequent filings with the United States Securities and Exchange Commission. All information contained in this press release is as of the date of this press release, and BeiGene does not undertake to update this information, except as required by law.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top